Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec;32(12):1365-1374.
doi: 10.1007/s10552-021-01484-4. Epub 2021 Aug 12.

Increasing prevalence of metastatic castration-resistant prostate cancer in a managed care population in the United States

Katrine L Wallace  1 , Adrienne Landsteiner  2 , Scott H Bunner  2 , Nicole M Engel-Nitz  2 , Amy N Luckenbaugh  3
Affiliations

Increasing prevalence of metastatic castration-resistant prostate cancer in a managed care population in the United States

Katrine L Wallace et al. Cancer Causes Control. 2021 Dec.

Abstract

Purpose: Numerous treatment breakthroughs for patients with metastatic castration-resistant prostate cancer (mCRPC) have been demonstrated in clinical trials in the past 15 years. However, real-world evidence on the changing epidemiology and longevity of this population has not been demonstrated. This study assessed prevalence trends for mCRPC over eight years in a large managed care population.

Methods: In a claims database, adult male patients were included with ≥ 1 claim for prostate cancer, pharmacologic/surgical castration, and metastatic disease during the identification period. The index mCRPC date was the first metastatic claim; six months of continuous enrollment before and after was required. Patients with metastatic disease at baseline were excluded. Patients were followed until death, end of study, or disenrollment, whichever was earliest. Total, mCRPC per-prostate cancer, and age-specific prevalence rates were calculated cross-sectionally for each year under study (2010-2017).

Results: Of 343,089 patients identified with a claim for prostate cancer, 3690 mCRPC cases (1.1%) were identified. Incidence (new cases per year) remained relatively constant over the study period while prevalence of mCRPC (total cases per year) increased. mCRPC prevalence increased with increasing age. Total and mCRPC per-prostate cancer prevalence rates increased in monotonic, year-over-year trends from 2010 to 2017, while incidence (new cases per year) of mCRPC remained relatively stable.

Conclusion: This study found increasing prevalence of mCRPC in an insured patient population during the 8-year period, coupled with stable incidence, validating that patients with the disease are living longer. With the addition of androgen receptor-directed therapies and poly(ADP-ribose) polymerase inhibitors in recent years, this trend will likely continue.

Keywords: Cancer epidemiology; Managed care; Prostate cancer; Real-world; mCRPC.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Siegel RL, Miller KD, Jemal A (2020) Cancer statistics. CA Cancer J Clin 70(1):7–30. https://doi.org/10.3322/caac.21590 - DOI
    1. Ritch C, Cookson M 2018 Recent trends in the management of advanced prostate cancer. F1000Res 7(F1000 Faculty Rev) Doi: https://doi.org/10.12688/f1000research.15382.1
    1. Scher HI, Solo K, Valant J, Todd MB, Mehra M (2015) Prevalence of prostate cancer clinical states and mortality in the United States: estimates using a dynamic progression model. PLoS ONE 10(10):e0139440. https://doi.org/10.1371/journal.pone.0139440 - DOI - PubMed - PMC
    1. Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN, Corn PG, de Bono JS, Dreicer R, George DJ, Heath EI, Hussain M, Kelly WK, Liu G, Logothetis C, Nanus D, Stein MN, Rathkopf DE, Slovin SF, Ryan CJ, Sartor O, Small EJ, Smith MR, Sternberg CN, Taplin ME, Wilding G, Nelson PS, Schwartz LH, Halabi S, Kantoff PW, Armstrong AJ (2016) Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol 34(12):1402–1418. https://doi.org/10.1200/jco.2015.64.2702 - DOI - PubMed - PMC
    1. Agency for Healthcare Research and Quality (2017) Clinical Classifications Software (CCS) for ICD-9-CM. www.hcup-us.ahrq.gov/toolssoftware/ccs/ccs.jsp . Accessed 16 February 2021

LinkOut - more resources